From Bench to Batch: What It Really Takes to Turn a Laboratory Formulation into a Commercial Product
By Vardan Ter-Antonyan
A formula can work perfectly in a beaker and still fail in production. I have seen it happen many times. The lab batch looks good, the test results are promising, and the launch team is ready to move. Then the product goes into a larger tank and behaves differently.
That gap between the bench and the production floor is where much of the real development work happens. Scale-up is not simply making more of the same formula. Larger equipment changes mixing, heating, cooling, and processing time. Pumps, filling lines, packaging, and shipping add conditions that never appeared in the laboratory.
This is especially true for poorly soluble compounds and advanced delivery systems such as nanoemulsions, liposomes, cyclodextrin complexes, and self-emulsifying systems. Small changes in ingredient grade, order of addition, temperature, shear, or water quality can affect particle size, clarity, viscosity, drug release, and shelf life.
One successful laboratory batch is not enough. Before scale-up begins, the team should know what the product must deliver. That includes dose, release rate, particle size, pH, viscosity, appearance, and shelf life. The team must also identify which ingredients and process steps have the greatest effect on those targets.
Current drug-delivery research is raising the bar. Long-acting injections, lipid nanoparticles, amorphous solid dispersions, oral peptide delivery, and targeted-release systems are moving into commercial pipelines. FDA includes ultra-long-acting oral formulations among the technologies accepted into its Emerging Technology Program. These products require tighter control over structure, release, and storage.
AI and computer models are being used to screen ingredients and reduce laboratory trials. They can guide the work, but they cannot replace physical testing, stability studies, or production batches.
On the manufacturing side, mixing is often the first problem. A small mixer may create strong circulation in a one-liter batch. A production tank may have dead zones or pull too much air into the product. Matching revolutions per minute does not mean the process has been matched. Impeller size, tank shape, tip speed, power per unit volume, and flow pattern all matter.
Heating and cooling also change with scale. Longer heating can degrade ingredients or change an emulsion, while slow cooling may cause crystallization. The process should therefore define acceptable ranges for temperature, mixing time, addition rate, shear, hold time, and pH.
Manufacturing itself is changing. Continuous manufacturing, Process Analytical Technology, and model-based controls allow companies to watch a process while it is running instead of relying only on finished-product testing. ICH Q13 provides a common framework for continuous manufacturing. FDA has also worked with companies on 3D printing, continuous aseptic spray drying, predictive models, closed-loop controls, and smaller distributed manufacturing platforms.
These technologies may shorten production time and reduce waste, but the team must know which measurements matter and what to do when the process drifts.
Quality and regulatory planning should start during development. Product category, intended use, claims, target market, and regulatory path affect ingredient limits, testing, labeling, and facility requirements. FDA’s Advanced Manufacturing Technologies Designation Program and Emerging Technology Program also give drug developers a way to discuss newer manufacturing approaches with the agency before making a major investment.
Commercial planning matters just as much. Recent supply shortages have increased interest in backup suppliers, domestic production, smaller manufacturing platforms, and faster technology transfer. A low ingredient price offers little value if the supplier cannot provide consistent material when it is needed.
In one project involving a poorly water-soluble active, a clear liquid performed well in the laboratory but developed a wider particle-size range and began separating after scale-up. The first suggestion was to add more emulsifier. That would have increased cost and worsened the taste.
The formula was not the problem. The larger tank had weaker circulation, the oil phase was added too quickly, and the batch remained hot for too long. We adjusted the addition rate, improved circulation, tightened the temperature range, and added an in-process particle-size check. The next batch met the target without changing the formula.
That case reflects a lesson I have carried through many development programs: the commercial product is not just the list of ingredients. It is that formula made through a defined process, on suitable equipment, with controlled materials. A product is ready to scale when the team understands how to make it consistently, not when one laboratory batch happens to work.
About the author
Vardan Ter-Antonyan is a scientist and R&D leader with more than 20 years of experience in formulation, drug delivery, process development, scale-up, and commercialization across pharmaceuticals, dietary supplements, medical devices, and consumer health products. Learn more at VardanTerAntonyan.com, visit Ter-Antonyan Consulting, or connect with him on LinkedIn. A professional headshot or custom feature image can be provided upon request.